Rocket One Inc. Reports $3.83 Million Net Loss in Q2 2026, Focuses on AI Infrastructure

Rocket One Inc. (formerly Hoth Therapeutics, Inc.) reported its financial results for the second quarter of 2026, revealing a net loss of approximately $3.83 million, or $0.19 per share, compared to a net loss of $2.20 million, or $0.17 per share, for the same period in 2025. The company did not generate any revenue during the quarter, consistent with its previous fiscal periods. For the six months ended June 30, 2026, the net loss increased to approximately $6.53 million from $5.68 million in the prior year. The total operating expenses for the second quarter were approximately $3.83 million, up from $2.20 million in the same quarter last year, driven primarily by increased research and development costs.

The company’s research and development expenses for the second quarter of 2026 were approximately $1.96 million, a significant increase from $1.04 million in the same quarter of 2025. This rise was attributed to costs associated with key projects, including approximately $1.63 million related to the HT-001 project and $35,000 for HT-VA. General and administrative expenses also rose to $1.88 million from $1.16 million, largely due to increased compensation and stock-based compensation expenses. The total operating expenses for the first half of 2026 reached approximately $6.48 million, compared to $5.68 million in the same period of 2025.

In terms of strategic developments, Rocket One Inc. has undergone a significant repositioning towards artificial intelligence (AI) infrastructure, focusing on semiconductor technologies for ultra-low-power AI applications. The company is developing several technologies, including a nanomagnetic matrix multiplier and Skyrmion Spintronic memory. Additionally, Rocket One has continued to advance its clinical assets under its subsidiary, Hoth Therapeutics LLC, which includes treatments for cancer side effects, obesity, and Alzheimer’s disease.

As of June 30, 2026, Rocket One reported total assets of approximately $9.58 million, an increase from $7.60 million at the end of 2025. The company’s cash and cash equivalents stood at approximately $7.89 million, up from $6.25 million at the end of the previous fiscal year. The increase in cash was primarily due to financing activities, including net proceeds of approximately $5.85 million from the issuance of common stock during the first half of 2026. The company’s accumulated deficit reached approximately $79.41 million as of June 30, 2026.

Looking ahead, Rocket One Inc. anticipates that it will require additional capital to fund its ongoing research and development activities and to meet its operational obligations. The company has indicated that it believes its current cash reserves will be sufficient to support its operations for at least the next 12 months. However, it will need to secure further funding through equity or debt financing to continue its strategic initiatives and product development.